Ligelizumab
Ligelizumab
Ligelizumab (pronounced li-ge-li-zu-mab) is a monoclonal antibody designed for the treatment of chronic spontaneous urticaria (CSU), a type of hives. It is developed by Novartis, a Swiss multinational pharmaceutical company.
Etymology
The name "Ligelizumab" is derived from the International Nonproprietary Names (INN), where "li-" refers to the immune system, "-ge-" denotes the target (IgE), "-li-" indicates the source (human), and "-zumab" is a suffix used for humanized monoclonal antibodies.
Mechanism of Action
Ligelizumab works by binding to the Immunoglobulin E (IgE), a type of antibody that plays a crucial role in the allergic response. By binding to IgE, Ligelizumab prevents it from attaching to cells and triggering an allergic reaction.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Chronic Spontaneous Urticaria (CSU): A condition characterized by the development of hives, angioedema, or both for at least six weeks due to unknown causes.
- Immunoglobulin E (IgE): A type of antibody that is primarily involved in allergic reactions.
- Novartis: A Swiss multinational pharmaceutical company that is one of the largest pharmaceutical companies in the world.
See Also
External links
- Medical encyclopedia article on Ligelizumab
- Wikipedia's article - Ligelizumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski